This Article Full Text (PDF) Other Versions of this Article: IAI.01495-07v1 76/5/2157    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Zhao, Z. Articles by Chen, H. Search for Related Content PubMed PubMed Citation Articles by Zhao, Z. Articles by Chen, H.

 Previous Article  |  Next Article 

Infect. Immun. doi:10.1128/IAI.01495-07
Copyright (c) 2008, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.

Subcutaneous vaccination with attenuated Salmonella choleraesuis C500 expressing recombinant filamentous haemagglutinin and pertactin antigens protects mice against fatal infections with both Salmonella choleraesuis and Bordetella bronchiseptica

State Key Laboratory of Agricultural Microbiology; Lab of Animal Infectious Diseases, College of Animal Science & Veterinary Medicine, Huazhong Agricultural University, Wuhan, Hubei, 430070, China

^* To whom correspondence should be addressed. Email: wub{at}mail.hzau.edu.cn. hzauvet{at}public.wh.hb.cn.

	Abstract

Salmonella choleraesuis C500 strain is a live, attenuated vaccine that has been used in China for over 40 years to prevent piglet paratyphoid. We compared the protective efficacy of subcutaneous (s.c.) and oral vaccination of BALB/c mice with C500 expressing the recombinant filamentous haemagglutinin type I domain and pertactin region 2 domain antigen (rF1P2) of Bordetella bronchiseptica. Protective efficacy was evaluated against both S. choleraesuis infection in an oral fatal challenge model, and B. bronchiseptica infection in a model of fatal acute pneumonia. Both the s.c. and oral vaccines conferred complete protection against fatal infection with the virulent parent S. choleraesuis strain (C78-1). All 20 mice vaccinated s.c. survived intranasal challenge with four times the 50% lethal dose of virulent B. bronchiseptica (HH0809) compared with 4 of 20 vector-treated controls and 1 of 18 phosphate-buffered saline (PBS)-treated controls that survived, but no significant protection against HH0809 was observed in orally vaccinated animals. Both the s.c. and oral vaccines elicited rF1P2-specific serum IgG and IgA antibodies. However, lung homogenates from s.c. vaccinated animals had detectably high levels of rF1P2-specific IgG and IgA; a much lower level of rF1P2-specific IgG was detected in samples from orally vaccinated mice, and the latter showed no evidence of local IgA. Furthermore, more abundant and longer persistence of vaccine organisms was observed in the lungs of mice immunized s.c. than those immunized orally. Our results suggest that s.c. rather than oral vaccination is more efficacious in protecting mice from fatal challenge with B. bronchiseptica.